Skip to Main Content

Karyopharm Therapeutics (KPTI) said Monday that the primary goal was achieved in a clinical trial designed to broaden the use of its cancer drug Xpovio to treat a larger number of patients with multiple myeloma.

Last July, the Food and Drug Administration approved Xpovio to treat patients with advanced multiple myeloma no longer responsive to at least four prior therapies. Based on results from the new clinical trial, Karyopharm intends to seek approval from the FDA to expand Xpovio’s label to treat so-called second-line multiple myeloma patients.


Karyopharm shares rose 38% to $22.50 in pre-market trading.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!